November 22nd 2024
Panelists discuss the data from the RESORCE trial, highlighting the efficacy of regorafenib in previously treated hepatocellular carcinoma, including primary trial results and insights on time to progression based on prior sorafenib treatment.
Panelists discuss the findings from the STELLAR trial, a phase 4 observational study presented at the European Society for Medical Oncology Congress 2024, which compares the efficacy of lenvatinib and sorafenib as first-line treatments for patients with advanced or unresectable hepatocellular carcinoma.
November 15th 2024
Panelists discuss the CELESTIAL trial findings and their implications for second-line treatment strategies in Japan for patients with previously treated hepatocellular carcinoma.
Panelists discuss the subgroup analyses from the CELESTIAL trial, focusing on treatment outcomes for specific patient populations with previously treated hepatocellular carcinoma.
November 8th 2024
Panelists discuss how to determine appropriate second-line and subsequent therapies for unresectable hepatocellular carcinoma after frontline treatment, emphasizing patient-specific factors and alternatives to clinical trial enrollment.
Panelists discuss findings from the IMmbrave050 trial comparing atezolizumab plus bevacizumab to active surveillance in patients with high-risk hepatocellular carcinoma patients, highlighting the significance of follow-up for those at risk of recurrence post- curative treatment.
October 25th 2024
Panelists discuss the findings from the EMERALD-1 trial on durvalumab with or without bevacizumab combined with transarterial chemoembolization TACE for first-line treatment of unresectable hepatocellular carcinomaHCC, examining its implications on progression-free survival, safety, and outcomes based on baseline tumor burden.
Panelists discuss the findings from the LEAP-012 study, which explores the efficacy of transarterial chemoembolization combined with lenvatinib and pembrolizumab in patients with Child-Pugh class A disease and intermediate-stage hepatocellular carcinoma.
Panelists discuss the results of the LEAP-012 study, highlighting the efficacy of transarterial chemoembolization combined with lenvatinib and pembrolizumab in patients with intermediate-stage hepatocellular carcinoma and Child-Pugh class A disease.
October 18th 2024
Panelists discuss the circumstances under which monotherapy with a tyrosine kinase inhibitor or immunotherapy would be preferred in the treatment of unresectable hepatocellular carcinoma.
Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.
October 7th 2024
Panelists discuss the current landscape of first-line treatment for unresectable hepatocellular carcinoma, highlighting key options and decision-making factors.
April 23rd 2024
Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, review locoregional therapies for hepatocellular carcinoma, including transarterial chemoembolization (TACE) and radioembolization.
April 16th 2024
The key opinion leaders discuss staging systems they use in clinical practice and their effectiveness in creating treatment algorithms, particularly with respect to Child-Pugh scores.
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss driving forces for the development of hepatocellular carcinoma, including different types of viral hepatitis and non-alcoholic steatohepatitis.
July 27th 2022
Key opinion leaders in breast cancer management share their excitement for data that will be released at the annual ASCO meeting in 2022 or the near future.
Before closing out their discussion on CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, experts highlight remaining unmet needs in this setting.